Executive Summary

Mission

Next-generation targeted endocannabinoid therapeutics for neurological disorders with improved safety and efficacy.

Mechanism of Action

Leverage the power of PPARɣ agonist pathway to administer cannabidiol in proprietary formulation for enhanced brain penetration.

Platform

Novel natural drug product derived from cannabidiol + proprietary formulation.

Current Status

Completed preclinical in-vivo studies using CQ-001.

Strategy

Best-in-class, fast-to-market strategy leveraging Epidiolex patient safety data to conduct bioequivalence (BE) study followed by Phase IIb/III study for NDA submission.

Raising Seed

$1.5M USD for IND-Enabling studies to completion of the BE study.